Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-03-25 | Kevin McLaughlin* Director 58 2015 ... In February 2015, the Board of Directors appointed Mr. McLaughlin to serve as a member of the Audit Committee. ... No director compensation was earned by Messrs. Gilman, McLaughlin and Wotton in 2014. |
| 2023-03-23 | Kevin McLaughlin has served as a Vericel Board member and the chair of its Audit Committee since 2015. Mr. McLaughlin has more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries. The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2022. Kevin McLaughlin received $70,000 in cash fees, $83,174 in stock awards, and $126,874 in option awards, totaling $280,048. |
| 2024-03-21 | Kevin McLaughlin, 67, Independent, Former Chief Financial Officer and Treasurer, Acceleron Pharma Inc., Director Since: 2015, Vericel Board committee(s): Audit (Chair) Committee, Director compensation total: $327,141 |
| 2025-03-20 | Kevin McLaughlin, 68 Independent Former Chief Financial Officer and Treasurer, Acceleron Pharma Inc. Director Since: 2015 Vericel Board committee(s): Audit (Chair) Committee Director compensation table: Total $439,898 |
Data sourced from SEC filings. Last updated: 2026-02-03